| **Author, Year** | **Did study attempt to enroll all (or a random sample of) patients meeting inclusion criteria, or a random sample (inception cohort)?** | **Were groups comparable at baseline on key prognostic factors?** | **Did study use accurate methods for ascertaining exposures and potential confounders?** | **Were outcome assessors and/or data analysts** **blinded to the exposure being studied?** | **Did article report attrition?** | **Did study perform appropriate statistical analyses on potential confounders?** | **Is there important differential loss to followup or overall high loss to followup?** | **Were outcomes prespecified, defined, and ascertained using accurate methods?** | **Quality rating** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Bedimo et al, 2011145 | Yes | No | Yes | Unclear | Yes | Yes | Differential: unclearHigh overall: no | Yes | Fair |
| DAD Study Group, 2010144 | Yes | Yes | Yes | Yes | Yes | Yes | Differential: unclearHigh overall: no | Yes | Good |
| DAD Study Group, 2008143 | Yes | Yes. A slightly higher proportion of patients with recent use of abacavir had a moderate to high CHD risk profile compared with recent use of other NRTIs (20% vs. 16–18%) | Yes | Yes | Yes | Yes | Differential: unclearHigh overall: no | Yes | Good |
| DAD Study Group, 2007142Other publication: Friis-Moller et al, 2003141 | Yes | Yes | Yes | Yes | Yes | Yes | Differential: unclearHigh overall: no | Yes | Good |
| Danish HIV Cohort Study, Obel et al, 2010146Other publications: Obel et al, 2008148; Lohse et al, 2006149 | Yes | Yes | Yes | Unclear | Yes | Yes | Differential: unclearHigh overall: no | Yes | Good |
| Ribaudo et al, 2011147 | Yes | Unclear | Yes | Yes | Yes | Yes | Differential: unclearHigh overall: no | Yes | Good |